Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 3, 2016, Pages 595-603

  Ueno, Hideki ^a   Ikeda, Masafumi ^b   Ueno, Makoto ^c   Mizuno, Nobumasa ^d   Ioka, Tatsuya ^e   Omuro, Yasushi ^f   Nakajima, Takako Eguchi ^g   Furuse, Junji ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYORIN UNIVERSITY   (Japan)

Author keywords

Combination chemotherapy; Gemcitabine; Nab paclitaxel; Pancreatic cancer; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; APREPITANT; DEXAMETHASONE; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; PALONOSETRON; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ACUTE PANCREATITIS; ADRENAL METASTASIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; BILIARY STENT; BLOOD TOXICITY; BONE METASTASIS; BRAIN INFARCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLOSTRIDIUM INFECTION; COLITIS; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPONATREMIA; JAPANESE (PEOPLE); LEUKOPENIA; LIVER METASTASIS; LOSS OF APPETITE; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84960101045     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-2972-3     Document Type: Article

References (26)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics 2012. CA Cancer J Clin 65:87-108
2. Japanese Ministry of Health, Labour and Welfare (2012) Statistical investigation result [in Japanese]. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei12/index.html. Accessed 27 Nov 2013
3. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
4. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
5. Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640-1648
6. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
7. Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin- bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324
8. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803
9. Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055-2062
10. Hosein PJ, de Lima Lopes G, Jr Pastorini VH et al (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36:151-156
11. Von Hoff DD, Ramanathan RK, Borad MJ et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548-4554
12. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703
13. Goldstein D, El-Maraghi RH, Hammel P et al (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst Jan 31 107(2):dju413
14. NCCN (2015) NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma version 2. NCCN. http://www.nccn.org/professionals/physician-gls/pdf/pancreatic.pdf. Accessed 28 May 2015
15. Ando M, Yonemori K, Katsumata N et al (2012) Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol 69:457-465
16. ® injection, 11 edn (2013) [in Japanese]. Eli Lilly Japan K.K. https://www.lilly.co.jp/lillyanswers/data/if/if-gem.pdf. Accessed 28 May 2015
17. Rochat B (2005) Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44:349-366
18. Bouffard DY, Laliberté J, Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45:1857-1861
19. Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135-1141
20. Japanese society of medical oncology (2012) Practical Guideline of Febrile Neutropenia (FN): Clinical Question 9, Treatment. [In Japansese]. Nankodo Co., Ltd. Tokyo, pp 22-23
21. Ueno H, Okusaka T, Funakoshi A et al (2007) A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 59:447-454
22. Okusaka T, Funakoshi A, Furuse J et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615-621
23. Okusaka T, Funakoshi A, Furuse J et al (2011) Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102:425-431
24. Okusaka T, Ikeda M, Fukutomi A et al (2014) Phase II study of FOLFIRINOX for chemotherapy-nalve Japanese patients with metastatic pancreatic cancer. Cancer Sci 105:1321-1326
25. Yanagimoto H, Ioka T, Ikeda M et al (2012) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study [In Japansese]. In: Paper presented at: 42th annual meeting of Japanese Pancreas Society
26. Garrido-Laguna I, Hidalgo M (2015) Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 12:319-334